Bamlanivimab Injection
RxNorm 2463117

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 2463117 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: bamlanivimab Injection.

The following semantic concepts and normalized strings are associated with this clinical entity:

SCDF
Bamlanivimab Injection
AUI:12509225
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SCDF

Semantic Clinical Drug Form (SCDF):
Bamlanivimab Injection
(Atom ID: 12509225)

Clinical Status & Identity

Prescribable Status
NO (Reference)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
bamlanivimab Injection
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2463117
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12509225
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SCDF
Semantic Clinical Drug Form (Ingredient + Dose Form)
Source Code
2463117
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Patient Education

Bamlanivimab Injection


Bamlanivimab injection is used to treat COVID-19 infection in certain non-hospitalized adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) and who have mild to moderate COVID-19 symptoms. It is used in people who have certain medical conditions that make them at higher risk for developing severe COVID-19 symptoms or the need to be hospitalized from COVID-19 infection. Bamlanivimab is in a class of medications called monoclonal antibodies. It works by blocking the action of a certain natural substance in the body to stop the spread of the virus.
[Learn More]


Bamlanivimab and Etesevimab Injection


The combination of bamlanivimab and etesevimab injection is used to treat COVID-19 infection in certain non-hospitalized adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) and who have mild to moderate COVID-19 symptoms. They are used in people who have certain medical conditions such as diabetes, immunosuppressive conditions, or kidney, heart, or lung disease that put them at higher risk for developing severe COVID-19 symptoms and/or needing to be hospitalized from COVID-19. Bamlanivimab and etesevimab are in a class called monoclonal antibodies. These medications work by blocking the action of a certain natural substance in the body to stop the spread of the virus.
[Learn More]


* Please review the disclaimer below.